HER2 positive gastric cancer is a distinct form of stomach cancer where tumors produce excessive amounts of a protein called HER2. This overproduction causes cancer cells to grow and spread faster, but it also opens the door to targeted treatments that specifically attack these cancer cells, offering new hope for patients facing this challenging disease.

Understanding HER2 Positive Gastric Cancer

Gastric cancer, commonly known as stomach cancer, affects thousands of people each year and remains a major health challenge worldwide. Within this broader category, HER2 positive gastric cancer represents a specific subtype that has become increasingly important in modern cancer care. This form of cancer is defined by the presence of elevated levels of the human epidermal growth factor receptor 2, or HER2, a protein that sits on the surface of cells and normally helps control their growth and division.

When cancer cells produce too much HER2, they develop an aggressive character and multiply at a faster rate than normal cells. This overexpression is found in approximately 15 to 20 percent of all gastric cancers, making it a significant subset of the disease.^[1][13] The discovery that HER2 plays a role in gastric cancer marked an important turning point, similar to what had been observed years earlier in breast cancer. This recognition led to the establishment of HER2 positive gastric cancer as its own disease entity, requiring specific testing and treatment approaches.^[1]

The condition also includes cancers of the gastroesophageal junction, which is the area where the esophagus meets the stomach. This junction area is particularly prone to HER2 positive tumors, with approximately 30 percent of gastroesophageal junction cancers testing positive for HER2, compared to about 15 percent of stomach cancers.^[7] Understanding whether a patient’s cancer is HER2 positive has become essential for planning the most effective treatment strategy.

Epidemiology

Gastric cancer ranks as the fifth most common cancer globally and the fourth leading cause of cancer-related deaths worldwide.^[13] In the United States, an estimated 43,280 new cases of gastroesophageal cancer are diagnosed each year, with approximately 26,420 deaths occurring annually from this disease.^[5] The burden is particularly heavy in certain regions, with gastric cancer being especially common in Asia, including countries such as China, Japan, and India.^[20]

The majority of patients with gastric cancer are diagnosed at advanced stages, with more than 80 percent of cases in some countries presenting as late-stage disease.^[13] This late diagnosis significantly affects outcomes and treatment options. When looking specifically at HER2 positive cases, approximately one in five people with stomach cancer has tumors that are HER2 positive.^[19] The demographic patterns show that the median age of patients diagnosed with HER2 positive gastric cancer is around 64 years, meaning half of patients are older and half are younger than this age.^[20]

For patients with advanced or metastatic gastric cancer, which means the cancer has spread to other parts of the body, the five-year survival rate ranges from only 5 to 10 percent.^[20] This sobering statistic highlights the severity of the disease and the critical importance of early detection and effective treatment strategies.

Causes

The root cause of HER2 positive gastric cancer lies in changes at the genetic and molecular level. The condition develops when there is an amplification of the ERBB2 gene, which is located on chromosome 17. This gene carries the instructions for making the HER2 protein.^[13] When this gene becomes amplified, meaning there are too many copies of it in the cell, the cancer cells produce excessive amounts of HER2 protein on their surface.

This overexpression of HER2 protein triggers a cascade of problematic cellular events. The excess HER2 proteins can pair up with other members of the epidermal growth factor receptor family, forming what scientists call heterodimers. This pairing activates various signaling pathways inside the cell that promote uncontrolled growth and division.^[13] These activated pathways essentially tell the cancer cells to keep growing, multiplying, and surviving when they should not.

The changes that lead to HER2 overexpression occur specifically in the cancer cells, not in all the cells of the body. This is why targeted therapies can be designed to attack the cancer cells while leaving normal cells relatively unharmed. The exact reasons why some gastric cancers develop HER2 amplification while others do not remain an area of active research. Unlike infectious diseases, HER2 positive gastric cancer is not transmitted from person to person and does not have a contagious component.

Risk Factors

While the specific risk factors that determine whether a gastric cancer will be HER2 positive are still being studied, general risk factors for developing gastric cancer include several lifestyle and health factors. These risk factors apply to all forms of gastric cancer, regardless of HER2 status, since the HER2 status is determined after the cancer has already developed.

Understanding the general landscape of gastric cancer risk can help individuals make informed decisions about prevention and screening. However, it is important to recognize that having risk factors does not mean a person will definitely develop cancer, and some people with no apparent risk factors may still develop the disease. The interplay between genetic susceptibility, environmental exposures, and lifestyle choices remains complex and not fully understood for this specific subtype of gastric cancer.

Symptoms

The symptoms experienced by patients with HER2 positive gastric cancer are not different from those of other types of gastric cancer. The HER2 status of the tumor does not change how symptoms present, but rather influences which treatments may be most effective.^[15] Understanding and recognizing these symptoms early can lead to more timely diagnosis and treatment.

Common symptoms of gastric cancer include difficulty swallowing, which occurs when tumors narrow the passage from the esophagus to the stomach. Patients often report feeling bloated or uncomfortably full after eating only small amounts of food, as the tumor takes up space in the stomach or affects its ability to expand normally.^[15] Persistent indigestion and heartburn that does not respond to typical remedies can also signal an underlying problem.

Many patients experience nausea and vomiting, which can occur because the tumor interferes with the stomach’s normal function or blocks the passage of food. Unexplained weight loss is particularly concerning, as it often indicates that the body is not properly absorbing nutrients or that the cancer is consuming significant energy.^[15] These symptoms can significantly impact a patient’s quality of life, affecting their ability to eat comfortably and maintain proper nutrition.

Prevention

There are currently no specific prevention strategies proven to prevent HER2 positive gastric cancer specifically, since the HER2 status is a characteristic that develops within an existing cancer rather than something that can be prevented independently. However, general measures to reduce the risk of developing gastric cancer may indirectly lower the risk of developing any subtype, including HER2 positive forms.

Information about specific dietary recommendations, lifestyle modifications, or screening approaches that might prevent HER2 positive gastric cancer is not available in the current medical literature. Research continues to explore whether certain factors might influence whether a gastric cancer becomes HER2 positive, but concrete preventive strategies remain to be established. The focus in clinical practice has shifted toward early detection and testing of existing cancers to identify HER2 status, which then guides treatment decisions.

Pathophysiology

The biological mechanisms underlying HER2 positive gastric cancer involve complex changes in how cells communicate and respond to growth signals. At the heart of this process is the HER2 protein, which belongs to a family of receptors called the epidermal growth factor receptor family. This family includes four members: EGFR (also known as HER1), HER2, HER3, and HER4.^[6]

In normal cells, HER2 receptors work as part of a carefully controlled system that regulates cell growth, division, and survival. When the ERBB2 gene becomes amplified in cancer cells, the cell produces far more HER2 protein than it should. These excess proteins cluster on the cell surface, creating an abnormal situation where growth signals are constantly being sent into the cell even when they should not be.^[13]

The HER2 proteins can pair with other members of the receptor family, forming partnerships that activate multiple signaling pathways inside the cell. These pathways include important cellular communication networks that control whether a cell grows, divides, or survives. When these pathways are constantly activated due to HER2 overexpression, cancer cells receive continuous instructions to multiply and resist normal death signals. This leads to rapid tumor growth and an increased ability of cancer cells to spread to other parts of the body, a process called metastasis.

One of the challenges in treating HER2 positive gastric cancer is that HER2 overexpression can vary within a single tumor. This heterogeneity means that some parts of the tumor may have high levels of HER2 while other parts have lower levels.^[6] This variation can affect how well targeted therapies work and may contribute to resistance when cancer cells with lower HER2 levels survive treatment and continue to grow.

The molecular changes in HER2 positive gastric cancer also affect how cancer cells respond to their environment and to treatments. The overactive signaling pathways make cells more aggressive and better at surviving under difficult conditions. They can promote the formation of new blood vessels that feed the tumor, help cancer cells invade surrounding tissues, and enable them to establish new tumors in distant organs. Understanding these mechanisms has been crucial for developing targeted therapies that can specifically block HER2 and its downstream effects.